Literature DB >> 30602761

mTOR as a central hub of nutrient signalling and cell growth.

Joungmok Kim1, Kun-Liang Guan2.   

Abstract

The highly conserved protein kinase mechanistic target of rapamycin (mTOR; originally known as mammalian target of rapamycin) is a central cell growth regulator connecting cellular metabolism and growth with a wide range of environmental inputs as part of mTOR complex 1 (mTORC1) and mTORC2. In this Review, we introduce the landmark discoveries in the mTOR field, starting from the isolation of rapamycin to the molecular characterizations of key components of the mTORC signalling network with an emphasis on amino acid sensing, and discuss the perspectives of mTORC inhibitors in therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30602761     DOI: 10.1038/s41556-018-0205-1

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  156 in total

Review 1.  Chemistry and biology of the immunophilins and their immunosuppressive ligands.

Authors:  S L Schreiber
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

2.  Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.

Authors:  H Baker; A Sidorowicz; S N Sehgal; C Vézina
Journal:  J Antibiot (Tokyo)       Date:  1978-06       Impact factor: 2.649

3.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Authors:  C Vézina; A Kudelski; S N Sehgal
Journal:  J Antibiot (Tokyo)       Date:  1975-10       Impact factor: 2.649

4.  The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.

Authors:  F J Dumont; M R Melino; M J Staruch; S L Koprak; P A Fischer; N H Sigal
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

5.  Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.

Authors:  F J Dumont; M J Staruch; S L Koprak; M R Melino; N H Sigal
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

Review 6.  Rapamycin: in vitro profile of a new immunosuppressive macrolide.

Authors:  S N Sehgal; C C Bansbach
Journal:  Ann N Y Acad Sci       Date:  1993-06-23       Impact factor: 5.691

7.  New antitumor substances of natural origin.

Authors:  J Douros; M Suffness
Journal:  Cancer Treat Rev       Date:  1981-03       Impact factor: 12.111

8.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

9.  Activity of rapamycin (AY-22,989) against transplanted tumors.

Authors:  C P Eng; S N Sehgal; C Vézina
Journal:  J Antibiot (Tokyo)       Date:  1984-10       Impact factor: 2.649

10.  Twenty-five years of mTOR: Uncovering the link from nutrients to growth.

Authors:  David M Sabatini
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-25       Impact factor: 11.205

View more
  245 in total

Review 1.  Immunometabolism in the development of rheumatoid arthritis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Immunol Rev       Date:  2020-01-27       Impact factor: 12.988

Review 2.  mTOR and other effector kinase signals that impact T cell function and activity.

Authors:  Darienne R Myers; Benjamin Wheeler; Jeroen P Roose
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 3.  Molecular Mechanisms of Lysosome and Nucleus Communication.

Authors:  Qian Zhao; Shihong Max Gao; Meng C Wang
Journal:  Trends Biochem Sci       Date:  2020-07-02       Impact factor: 13.807

4.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 5.  Lysosome biology in autophagy.

Authors:  Willa Wen-You Yim; Noboru Mizushima
Journal:  Cell Discov       Date:  2020-02-11       Impact factor: 10.849

6.  Mycobacterium tuberculosis (Mtb) lipid mediated lysosomal rewiring in infected macrophages modulates intracellular Mtb trafficking and survival.

Authors:  Kuldeep Sachdeva; Manisha Goel; Malvika Sudhakar; Mansi Mehta; Rajmani Raju; Karthik Raman; Amit Singh; Varadharajan Sundaramurthy
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

Review 7.  mTOR in Lung Neoplasms.

Authors:  Ildiko Krencz; Anna Sebestyen; Andras Khoor
Journal:  Pathol Oncol Res       Date:  2020-02-03       Impact factor: 3.201

Review 8.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

Review 9.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

10.  The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.

Authors:  Shuling Zhang; Wei Shi; Edward S Ramsay; Valery Bliskovsky; Adrian Max Eiden; Daniel Connors; Matthew Steinsaltz; Wendy DuBois; Beverly A Mock
Journal:  J Biol Chem       Date:  2019-09-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.